Using Atenolol in Parkinson's Disease Patients with Heart Failure

Selection of Beta-Blocker

Beta-blockers like atenolol can be used in Parkinson's disease patients with heart failure, but hydrophilic beta-1 selective agents are preferred to minimize neuropsychiatric side effects, according to the European Society of Cardiology 1
Atenolol, being a hydrophilic beta-1 selective agent, is preferred over lipophilic beta-blockers for Parkinson's disease patients as it has less potential to exacerbate symptoms of depression or cognitive issues, as recommended by the European Society of Cardiology 1

Double the dose at not less than 2-week intervals if the preceding dose was well tolerated, as suggested by the European Journal of Heart Failure and the European Heart Journal 3, 4
Monitor heart rate, blood pressure, and clinical status during titration, according to the European Journal of Heart Failure and the European Heart Journal 3, 5

Monitor for orthostatic hypotension, which may be exacerbated in Parkinson's patients who often have autonomic dysfunction, as recommended by the European Society of Cardiology 1
Assess for bradycardia carefully, as both Parkinson's medications and beta-blockers can affect heart rate, according to the European Heart Journal 4
Avoid abrupt discontinuation of beta-blockers due to risk of "rebound" increases in myocardial ischemia/infarction and arrhythmias, as warned by the European Journal of Heart Failure 6

For worsening heart failure symptoms, first increase the dose of diuretics or ACE inhibitor before reducing the beta-blocker dose, as recommended by the European Heart Journal and the European Journal of Heart Failure 4, 7
If symptoms persist despite diuretic adjustment, temporarily reduce the atenolol dose by 50%, according to the European Journal of Heart Failure 3

Regular assessment of heart rate, blood pressure, and clinical status during initiation and dose adjustments, as suggested by the European Journal of Heart Failure 3
Monitor for worsening of Parkinson's symptoms, particularly depression, which may be exacerbated by beta-blockers, as recommended by the European Society of Cardiology 1

For patients with severe heart failure (NYHA class III/IV), as recommended by the European Heart Journal 4
When relative contraindications exist (asymptomatic bradycardia, low blood pressure), according to the European Heart Journal 8
If there is intolerance to low doses of beta-blockers, as suggested by the European Heart Journal 4